Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 2Rheumatoid Arthritis, Systemic Juvenile 1Periodic Fevers Syndrome 1Mevalonate Kinase Deficiency 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma 1Cryopyrin-Associated Periodic Syndromes 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Arthritis, Juvenile 1Arthralgia 1

Interventions

tofacitinib 7ibrutinib 4Rituximab 4Imatinib Mesylate 3ruxolitinib 2ofatumumab 2obinutuzumab 2nilotinib 2bosutinib 2sodium luminolate 1posaconazole 1pegfilgrastim 1montelukast 1ixekizumab 1fludarabine 1canakinumab 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Sirolimus 1Ribavirin 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bronchiolitis Obliterans Syndrome × canakinumab × Clear all
NCT02334748 2020-05-19

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Novartis

Phase 3 Completed
31 enrolled 7 charts

Rheumatoid Arthritis, Systemic Juvenile, Bronchiolitis Obliterans Syndrome, Arthritis, Juvenile, Arthralgia, Mevalonate Kinase Deficiency, Cryopyrin-Associated Periodic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡